Dr Jeanne Tie is a medical oncology staff specialist at the Peter MacCallum Cancer Centre and the Western Hospital, and a Senior Clinical Research Fellow at the Walter and Eliza Hall Institute of Medical Research. After completing her specialty training at the Royal Melbourne Hospital, she undertook a laboratory-based postgraduate research study at the Ludwig Institute for Cancer Research focusing on understanding prognostic and predictive molecular biomarkers in colorectal cancer. Her research work was recognised by several prestigious awards (ASCO Cancer Foundation Young Investigator Award and the Bradley Stuart Beller Merit Award). Dr Tie was recently awarded the Victorian Cancer Agency Research Fellowship and Early Career Seed Grant to support her translational research focusing on the clinical applications of circulating tumour DNA in colorectal cancer. Dr Tie's clinical research interests are in the drug development and management of colorectal cancer and thyroid cancer.
Western Health Best Research Poster Award (2014)
AGITG (Australasian Gastro-Intestinal Trials Group) Annual Scientific Meeting Best of Posters Award (2013)
American Society of Clinical Oncology (ASCO) Cancer Foundation Young Investigator Award (2010)
ASCO Bradley Stuart Beller Merit Award (2009)
Victorian Cancer Agency Early Career Bench and Bedside Collaboration Award (2008)
1. J. Tie, L. Lipton, J. Desai, P. Gibbs, R.N. Jorissen, M. Christie, K.J. Drummond, B N.J.Thomson, V. Usatoff, P.M. Evans, A.W. Pick, P.W.G. Carne, Q. Zhao, D. Busam, R.L. Strausberg, E. Domingo, I.P.M. Tomlinson, R. Midgley, D. Kerr and O.M. Sieber. KRAS Mutation is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer. Clinical Cancer Research. 2011;17(5):1122-1130.
2. J. Tie, P. Gibbs, L. Lipton, M. Christie, T. Burgess, R. Jorissen, R. Langland, S. Cheng, S. Kosmider, D. McKay, G. Bollag, K. Nolop, O. Sieber, J. Desai. Optimising targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation. Int J Cancer. 2011;128(9):2075-84.
3. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014 Feb 19;6(224):224ra24.
4. J. Tie, I. Kinde, Y. Wang, H.L. Wong, J. Roebert, M. Christie, M. Tacey, R. Wong, M. Singh, C. S. Karapetis, J. Desai, B. Tran, R. Strausberg, L. A. Diaz Jr, N. Papadopoulos, K.W. Kinzler, B. Vogelstein, P. Gibbs. Circulating Tumor DNA as an Early Marker of Therapeutic Response in Patients with Metastatic Colorectal Cancer. Ann Oncol. 2015 Aug;26(8):1715-22.
Clinical applications of Circulating tumour DNA in colorectal cancer, biomarker development in colorectlal cancer
Clinical trials (including early phase) in colorectal cancer